We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vectura Group Plc | LSE:VEC | London | Ordinary Share | GB00BKM2MW97 | ORD 0.0271P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 164.80 | 164.80 | 165.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVEC
RNS Number : 7076N
Vectura Group plc
26 September 2019
Board Change
Chippenham, UK - 26 September 2019: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") announces that Dr Susan Foden is stepping down from the Board and her role as Senior Independent Non-Executive Director of Vectura. This change takes effect on 30 September 2019.
Dr Foden is the longest current serving Director of the Group, having been a Board member since 2007. Currently a member of the Nomination Committee, she has also chaired the Group's Remuneration Committee and has been a member of the Audit Committee.
Dr Thomas Werner will replace Dr Foden as Senior Independent Non-Executive Director.
Bruno Angelici, Chairman of the Board, said: "I would like to recognise Susan's significant contributions to Vectura and thank her for her commitment to the Group over the past 12 years. She has provided valuable insight and expertise in her roles across the Board and our Committees. We all wish her every success for the future."
- Ends-
For more information, please contact:
Vectura Group plc
David Ginivan - VP Corporate Communications +44 (0)7471 352 720 Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / David Daley +44 (0)20 3709 5700
Notes
About Vectura
Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.
Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.
For further information, please visit Vectura's website at www.vectura.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
BOAEAFNSALPNEAF
(END) Dow Jones Newswires
September 26, 2019 04:00 ET (08:00 GMT)
1 Year Vectura Chart |
1 Month Vectura Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions